• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » First patients implanted with Orthofix Legacy demineralized bone matrix

First patients implanted with Orthofix Legacy demineralized bone matrix

October 13, 2022 By Sean Whooley

OrthoFix legacy demineralized bone matrix DBM
The Legacy DBM. [Image from Orthofix]
Orthofix (Nasdaq:OFIX) announced today that it completed the full market release and first implants of its Legacy demineralized bone matrix (DBM).

Lewisville, Texas-based Orthofix designed the Legacy DBM as a putty for filling voids or gaps. It operates in boney defects or traumatic injuries of the spine, pelvis or extremities.

MTF Biologics processes the Legacy DBM, according to a news release. Its tailored processing methods preserve the inherent growth factors natural to the bone.

Dr. Alan Daniels, chief of spine surgery at University Orthopedics in Providence, Rhode Island, implanted the first patient.

“Bone healing is a dynamic process where multiple factors play an integral role in deciding which biologic best meets the individual needs of the patient to aid them on their road to recovery,” said Daniels. “Legacy DBM provides a cost-effective option, without compromising clinical experience or the handling needed in a bone matrix.”

Orthofix adds to its growing portfolio

The puttylike consistency of Legacy DBM offers desirable handling, Orthofix said. Its uses include as an extender with autograft or allograft or with bone marrow aspirate. Legacy DBM joins a range of Orthofix’s recently introduced offerings through its exclusive partnership with MTF Biologics. That includes the Virtuous lyograft, Trinity Elite FiberFuse advanced and FiberFuse Strip allografts and the Alloquent structural allograft portfolio.

“The Legacy DBM is another example of our continued commitment to expand biologic offerings to meet the needs of surgeons and their patients. In the past year alone, we have introduced five new biologics including the Virtuos Lyograft, a first-of-its-kind, shelf-stable, and complete autograft substitute,” said Kevin Kenny, Orthofix president of global spine. “In addition, we recently announced a partnership with CGBio, a developer of innovative bone grafts, representing the first step in bringing Novosis – the next evolution in bone growth factor technology – to the U.S. and Canadian markets.

“We understand there are unique surgeon users for a wide range of bone-grafting options, and it is our goal to be a leading provider of these biologic offerings to our customers.”

The news comes just days after Orthofix announced a major merger in the orthopedic space. The company combined with SeaSpine in an all-stock merger of equals on Oct. 11.

Filed Under: Business/Financial News, Implants, Orthopedics Tagged With: Orthofix

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy